RE-BVS – Piemonte Repository

Sfoglia per AUTORE
VISSEREN-GRUL C
Collezione AOU San Luigi di Orbassano

Items : 6

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032.

2024
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Aix SP; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Nishino K; Yoh K; Shih JY; Chik JYK; Moro-Sibilot D; Puri T; Chacko Varughese S; Frimodt-Moller B; Visseren-Grul C; Reck M;

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. in Cancer treatment and research communications / Cancer Treat Res Commun. 2021;27:100378. doi: 10.1016/j.ctarc.2021.100378. Epub 2021 Apr 19.

2021
AOU San Luigi di Orbassano

Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.

2019
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;

Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2015 May;88(2):160-6. doi: 10.1016/j.lungcan.2015.02.014. Epub 2015 Feb 23.

2015
AOU San Luigi di Orbassano

Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S;

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2014 Sep;85(3):408-14. doi: 10.1016/j.lungcan.2014.07.005. Epub 2014 Jul 16.

2014
AOU San Luigi di Orbassano

Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG;

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2009 Sep;45(13):2298-303. doi: 10.1016/j.ejca.2009.04.033. Epub 2009 May 25.

2009
AOU San Luigi di Orbassano

Scagliotti GV; Park K; Patil S; Rolski J; Goksel T; Martins R; Gans SJ; Visseren-Grul C; Peterson P;